Success Metrics

Clinical Success Rate
100.0%

Based on 2 completed trials

Completion Rate
100%(2/2)
Active Trials
0(0%)
Results Posted
0%(0 trials)

Phase Distribution

Ph phase_2
4
80%
Ph phase_1
1
20%

Phase Distribution

1

Early Stage

4

Mid Stage

0

Late Stage

Phase Distribution5 total trials
Phase 1Safety & dosage
1(20.0%)
Phase 2Efficacy & side effects
4(80.0%)

Highest Phase Reached

Phase 2

Trial Status & Enrollment

Completion Rate

40.0%

2 of 5 finished

Non-Completion Rate

60.0%

3 ended early

Currently Active

0

trials recruiting

Total Trials

5

all time

Status Distribution
Completed(2)
Terminated(3)

Detailed Status

Withdrawn3
Completed2

Development Timeline

Analytics

Development Status

Total Trials
5
Active
0
Success Rate
100.0%
Most Advanced
Phase 2

Trials by Phase

Phase 11 (20.0%)
Phase 24 (80.0%)

Trials by Status

withdrawn360%
completed240%

Recent Activity

0 active trials
Showing 5 of 5
withdrawnphase_2

Efficacy and Safety of Weekly Subcutaneous MLN1202 in Improving Diabetic Nephropathy in Participants With Macroalbuminuria

NCT02410499
withdrawnphase_1

Phase 1 Single Subcutaneous Dose Study of MLN1202

NCT02426021
withdrawnphase_2

Proof of Mechanism Study of MLN1202 on Atherosclerotic Inflammation in Participants With Stable Atherosclerotic Cardiovascular Disease

NCT02388971
completedphase_2

Study of the Safety and Efficacy of MLN1202 in Patients in Multiple Sclerosis

NCT01199640
completedphase_2

Double-Blind, Randomized, Placebo-Controlled Trial of MLN1202 on C-Reactive Protein Levels in Patients With Risk Factors for Cardiovascular Disease

NCT00715169

Clinical Trials (5)

Showing 5 of 5 trials
NCT02410499Phase 2

Efficacy and Safety of Weekly Subcutaneous MLN1202 in Improving Diabetic Nephropathy in Participants With Macroalbuminuria

Withdrawn
NCT02426021Phase 1

Phase 1 Single Subcutaneous Dose Study of MLN1202

Withdrawn
NCT02388971Phase 2

Proof of Mechanism Study of MLN1202 on Atherosclerotic Inflammation in Participants With Stable Atherosclerotic Cardiovascular Disease

Withdrawn
NCT01199640Phase 2

Study of the Safety and Efficacy of MLN1202 in Patients in Multiple Sclerosis

Completed
NCT00715169Phase 2

Double-Blind, Randomized, Placebo-Controlled Trial of MLN1202 on C-Reactive Protein Levels in Patients With Risk Factors for Cardiovascular Disease

Completed

All 5 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
5